VoyForums
[ Show ]
Support VoyForums
[ Shrink ]
VoyForums Announcement: Programming and providing support for this service has been a labor of love since 1997. We are one of the few services online who values our users' privacy, and have never sold your information. We have even fought hard to defend your privacy in legal cases; however, we've done it with almost no financial support -- paying out of pocket to continue providing the service. Due to the issues imposed on us by advertisers, we also stopped hosting most ads on the forums many years ago. We hope you appreciate our efforts.

Show your support by donating any amount. (Note: We are still technically a for-profit company, so your contribution is not tax-deductible.) PayPal Acct: Feedback:

Donate to VoyForums (PayPal):

[ Login ] [ Contact Forum Admin ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: 1, [2] ]

[ Next Thread | Previous Thread | Next Message | Previous Message ]

Date Posted: 12:56:56 08/08/03 Fri
Author: Michael Caracozza
Subject: Funding needed for Biotechnology Firm

DIAGEN Corporation is a Research & Development biomedical company, currently focusing its efforts on developing simple, cost-effective blood test kits to improve early diagnosis, prognosis, and monitoring response to treatment for cancer, autoimmune disorders and infectious diseases. DIAGEN has established a business model built on ‘platform technology’, which will generate an ongoing revenue stream of advanced type products starting in year one, addressing a multi-billion dollar market potential. A unique perspective on the immune system, and related immunochemistry defines the core of DIAGEN’s ImmunoTechnology. The current inadequacy in therapeutics and diagnostics is shown most clearly in the lack of reliable biomarkers. Early detection is critical yet often prevented by biomarkers being hidden within molecular conglomerates. Currently no direct, efficient or rapid method exists to make either of the above determinations for a host of conditions. This blood test technology will provide several advantages over current, existing technologies which include: a simple, cost-effective and reliable blood test that will provide early screening, diagnosis, prognosis, and monitoring of the response to treatment of cancer patients, autoimmune patients and various infectious disease patients. More specifically, DIAGEN’s blood tests will be capable of detecting the presence of tumors before currently available diagnostics, while indicating how well or poorly the patient’s immune system is dealing with the tumor. DIAGEN’s blood tests are unique because they measure the immune response to the cancer in addition to detecting the presence of tumor markers. Pharmaceutical and discovery companies for screening and / or discovery of therapeutic drug and vaccine targets can use these technologies as well. DIAGEN’s primary customers will include; oncologists, hematologists, immunologists, rheumatologists and lab directors located in hospitals and centralized reference labs worldwide. Marketing strategy will include: Manufacture and sell customized reagent products to blood test kit companies – 3-6 months; secure corporate partnering to sub-contract or license blood test products to market leaders - approximately 12 – 18 months to receive approval and launch its first clinically tested blood test kit for breast cancer and prostate cancer; license / royalty agreements for discovery technologies w/ Biopharma companies . Competition:There are several leading diagnostic companies of which Abbott Laboratories is recognized as a major player. However, the diagnostic market is vast and fragmented. Diagen’s management team is comprised of the President / CEO (also is the founder) who has extensive experience in the medical industry from a business perspective. The V-P of Research & Development who is also the scientist responsible for the development of the science has many years of experience in this area as an immunologist and microbiologist. The Board of Scientific Advisors took interest because of the ‘need’ for better diagnostic modalities when it comes to early detection and treatment of cancer and other diseases. DIAGEN is seeking an initial investment of $1,500,000 followed by an additional $8,000,000 starting in year two. These funds will be used to generate immediate revenue from existing products, key hires, research and development activities, establish lab facility in North Carolina, seek FDA 510 (k) approval for breast cancer blood test kit, working capital and general corporate purposes. DIAGEN projects to be profitable in year two.

[ Next Thread | Previous Thread | Next Message | Previous Message ]
[ Contact Forum Admin ]

Forum timezone: GMT-8
VF Version: 3.00b, ConfDB:
Before posting please read our privacy policy.
VoyForums(tm) is a Free Service from Voyager Info-Systems.
Copyright © 1998-2019 Voyager Info-Systems. All Rights Reserved.